Alexion Board Rejects Stakeholder Recommendation to Sell the Company | BioSpace
iCo Therapeutics Partners with Top 15 Biotech Company Alexion Pharmaceuticals for the Development and Commercialization of iCo-008 | T-Net News
Alexion Pharmaceuticals et Moderna Therapeutics annoncent un accord stratégique exclusif de développement de messenger RNA Therapeutics™ pour les maladies rares | Business Wire
aHUS Alliance - Recent launch of Alexion Pharmaceuticals site https://www.ultomiris.com/ provides info on ravulizumab, now approved by the FDA as a longer acting complement inhibitor to treat the rare disease PNH. Click
Alexion Says FDA Grants Orphan Drug Designation To ALXN1210 | World Pharma Today
Alexion holds 97.7 percent of the shares in Wilson Therapeutics after the initial acceptance period and declares the offer uncon
Verge Genomics collaborates with AstraZeneca's Alexion
Alexion's Ultomiris Hits Mark in Phase III for Myasthenia Gravis | BioSpace
ex995wtxofferstatement
Alexion Completes Purchase and License Agreement of Rare Disease Gene Therapy Portfolio from Pfizer
Press Release: Alexion Receives FDA Approval of SOLIRIS for NMO
AstraZeneca plots post-COVID future with $39 billion Alexion deal | Business – Gulf News
Alexion publishes a supplement to the offer document regarding its recommended cash offer to the shareholders in Wilson Therapeu
MDA Celebrates FDA Approval of Alexion's Ultomiris for Treatment of gMG
Alexion leaders talk research, booming biotech industry in New Haven - Yale Daily News
AstraZeneca reçoit l'approbation de l'UE pour son Saphnelo, le seul nouveau médicament depuis plus d'une décennie pour les patients atteints de lupus érythémateux disséminé | EuropaWire.eu | The European Union's press release
Emergency Alexion chief Brennan says he's '120% committed' to righting the company ship | Fierce Pharma
Press Release
Ipsen announces change in R&D leadership: Howard Mayer to retire, succeeded by Christelle Huguet
Sandeep Talamudupula on LinkedIn: Press Releases | Alnylam Pharmaceuticals
Skanska Announces 121 Seaport Fully Leased as Alexion Pharmaceuticals Moves Headquarters to the Office Development | www.usa.skanska.com
Alexion Reports Second Quarter 2018 Results
Nos actualités – Ad Scientiam
PharmaShots | Incisive News in 3 Shots
Wendy Erler sur LinkedIn : As we lead into Rare Disease Day 2023, we share this important work with…
![Press Release] Nava Health Announces Expansion into Boca Raton and Plantation, Florida, with Technology-Driven Approach to Integrative Medicine - Nava Health](https://navacenter.com/wp-content/uploads/2023/12/IMG_4155-rotated.jpg "Press Release] Nava Health Announces Expansion into Boca Raton and Plantation, Florida, with Technology-Driven Approach to Integrative Medicine - Nava Health")
Press Release] Nava Health Announces Expansion into Boca Raton and Plantation, Florida, with Technology-Driven Approach to Integrative Medicine - Nava Health
